“XELOX + Bevacizumab compared to FOLFOX4 + Bevacizumab in First line Metastatic Colorectal Cancer in a Non-reimbursed Health Care System: A Cost Analysis”, Acta Med Philipp, vol. 49, no. 2, Jun. 2015, doi: 10.47895/amp.v49i2.988.